Is Editas Medicine, Inc. (EDIT) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 17.9% / 30% | 138.2% / 30% | 8.3% / 30% | 43.52% / 5% | ✗ NOT HALAL |
| DJIM | 17.9% / 33% | 138.2% / 33% | 8.3% / 33% | 43.52% / 5% | ✗ NOT HALAL |
| MSCI | 10.3% / 33% | 79.0% / 33% | 4.8% / 33% | 43.52% / 5% | ✗ NOT HALAL |
| S&P | 17.9% / 33% | 138.2% / 33% | 8.3% / 33% | 43.52% / 5% | ✗ NOT HALAL |
| FTSE | 10.3% / 33% | 79.0% / 33% | 4.8% / 50% | 43.52% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | -122.0% | |
| Operating Margin | -56.7% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -198.1% | |
| Return on Assets (ROA) | -23.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$165M |
| Free Cash Flow | -$166M |
| Total Debt | $18M |
| Debt-to-Equity | 66.3 |
| Current Ratio | 3.5 |
| Total Assets | $187M |
Price & Trading
| Last Close | $2.32 |
| 50-Day MA | $2.11 |
| 200-Day MA | $2.58 |
| Avg Volume | 1.8M |
| Beta | 2.2 |
|
52-Week Range
$0.91
| |
About Editas Medicine, Inc. (EDIT)
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Editas Medicine, Inc. (EDIT) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Editas Medicine, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Editas Medicine, Inc.'s debt ratio?
Editas Medicine, Inc.'s debt ratio is 17.9% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 10.3%.
What are Editas Medicine, Inc.'s key financial metrics?
Editas Medicine, Inc. has a market capitalization of $218M, and revenue of $41M. Return on equity stands at -198.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.